Use of a GH receptor antagonist (GHRA) to explore the relationship between GH and IGF-I in adults with severe GH deficiency (GHD).

Berg CA, Pokrajac A, Bidlingmaier M, Strasburger CJ, Shalet SM, Trainer PJ

Clinical endocrinology3 Dec 2008Cited by 9 (Europe PMC)

PMID19067728DOI10.1111/j.1365-2265.2008.03481.xPepBankPUB-19067728

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

01HumanNon-randomized trialEfficacy outcome
In healthy volunteers, pegvisomant decreased IGF-I from 158.5 to 103 microg/l (P < 0.01).
In plain wordsIn healthy volunteers, IGF-I was lower with pegvisomant.
Peptide
Pegvisomant
Outcome
DecreaseIGF-I in healthy volunteers
Study
n: not reported in source
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
20 mg daily · 14 daysAs given in this study (human).
Measurements
IGF-I
158.5 microg/l
reference
IGF-I
103 microg/l
pegvisomant
Source sentences
Summary
Pegvisomant decreased IGF-I in CONS and NORMS [158.5 (101-206) vs. 103 (77-125) microg/l, P < 0.01; 124 (81-136) vs. 95 (51-113) microg/l, P < 0.01 respectively]
1 context sentence(design, population, supporting numbers)
Summary · context
We performed a double-blind, randomized, placebo-controlled, cross-over study to investigate the effect of the GH receptor antagonist - pegvisomant (20 mg daily for 14 days) on GH and IGF-I levels in three cohorts: patients with GHD and a normal IGF-I (NORMS); patients with GHD and a low IGF-I (LOWS…
Report a problemFND-1906772801
02HumanNon-randomized trialEfficacy outcome
In GHD patients with normal IGF-I, pegvisomant decreased IGF-I from 124 to 95 microg/l (P < 0.01).
In plain wordsIn growth hormone deficiency with normal IGF-I, IGF-I was lower with pegvisomant.
Peptide
Pegvisomant
Outcome
DecreaseIGF-I in normal-IGF-I GHD
Study
n: not reported in source
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
20 mg daily · 14 daysAs given in this study (human).
Measurements
IGF-I
124 microg/l
reference
IGF-I
95 microg/l
pegvisomant
Source sentences
Summary
Pegvisomant decreased IGF-I in CONS and NORMS [158.5 (101-206) vs. 103 (77-125) microg/l, P < 0.01; 124 (81-136) vs. 95 (51-113) microg/l, P < 0.01 respectively]
1 context sentence(design, population, supporting numbers)
Summary · context
We performed a double-blind, randomized, placebo-controlled, cross-over study to investigate the effect of the GH receptor antagonist - pegvisomant (20 mg daily for 14 days) on GH and IGF-I levels in three cohorts: patients with GHD and a normal IGF-I (NORMS); patients with GHD and a low IGF-I (LOWS…
Report a problemFND-1906772802
03HumanNon-randomized trialEfficacy outcome
In GHD patients with low IGF-I, pegvisomant did not decrease IGF-I (31 versus 34.5 microg/l).
In plain wordsIn growth hormone deficiency with low IGF-I, pegvisomant did not lower IGF-I.
Peptide
Pegvisomant
Outcome
No significant changeIGF-I in low-IGF-I GHD
Study
n: not reported in source
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
20 mg daily · 14 daysAs given in this study (human).
Measurements
IGF-I
31 microg/l
reference
IGF-I
34.5 microg/l
pegvisomant
Source sentences
Summary
but not in LOWS [31 (< 31-32) vs. 34.5 (< 31-38) microg/l]
1 context sentence(design, population, supporting numbers)
Summary · context
We performed a double-blind, randomized, placebo-controlled, cross-over study to investigate the effect of the GH receptor antagonist - pegvisomant (20 mg daily for 14 days) on GH and IGF-I levels in three cohorts: patients with GHD and a normal IGF-I (NORMS); patients with GHD and a low IGF-I (LOWS…
Report a problemFND-1906772803
04HumanNon-randomized trialEfficacy outcome
In healthy volunteers, the pegvisomant-induced IGF-I fall was associated with an increase in mean 24 h GH from 0.49 to 1.38 microg/l (P = 0.03).
In plain wordsIn healthy volunteers, pegvisomant was associated with higher mean growth hormone.
Peptide
Pegvisomant
Outcome
IncreaseMean GH in healthy volunteers
Study
n: not reported in source
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
20 mg daily · 14 daysAs given in this study (human).
Measurements
GH
0.49 microg/l
reference
GH
1.38 microg/l
pegvisomant
Source sentences
Summary
and this was associated with an increase in mean 24 h GH in CONS [0.49 (0.12-0.89) to 1.38 (0.22-2.45) microg/l (P = 0.03)]
1 context sentence(design, population, supporting numbers)
Summary · context
We performed a double-blind, randomized, placebo-controlled, cross-over study to investigate the effect of the GH receptor antagonist - pegvisomant (20 mg daily for 14 days) on GH and IGF-I levels in three cohorts: patients with GHD and a normal IGF-I (NORMS); patients with GHD and a low IGF-I (LOWS…
Report a problemFND-1906772804
05HumanNon-randomized trialEfficacy outcome
In GHD patients with normal IGF-I, the pegvisomant-induced IGF-I fall was associated with an increase in mean 24 h GH of 69%, from 0.1 to 0.17 microg/l (P = 0.03).
In plain wordsIn growth hormone deficiency with normal IGF-I, pegvisomant was associated with higher growth hormone.
Peptide
Pegvisomant
Outcome
IncreaseMean GH in normal-IGF-I GHD
Study
n: not reported in source
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
20 mg daily · 14 daysAs given in this study (human).
Measurements
GH increase
69%
reported result
GH
0.1 microg/l
reference
GH
0.17 microg/l
pegvisomant
Source sentences
Summary
and in NORMS [69 (0-320)% from 0.1 (< 0.1-0.13) to 0.17 (0.11-0.42) microg/l (P = 0.03)], but not in the LOWS.
1 context sentence(design, population, supporting numbers)
Summary · context
We performed a double-blind, randomized, placebo-controlled, cross-over study to investigate the effect of the GH receptor antagonist - pegvisomant (20 mg daily for 14 days) on GH and IGF-I levels in three cohorts: patients with GHD and a normal IGF-I (NORMS); patients with GHD and a low IGF-I (LOWS…
Report a problemFND-1906772805
06HumanNon-randomized trialEfficacy outcome
In GHD patients with low IGF-I, pegvisomant did not increase mean GH.
In plain wordsIn growth hormone deficiency with low IGF-I, pegvisomant did not increase mean growth hormone.
Peptide
Pegvisomant
Outcome
No significant changeMean GH in low-IGF-I GHD
Study
n: not reported in source
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
20 mg daily · 14 daysAs given in this study (human).
Source sentences
Summary
and this was associated with an increase in mean 24 h GH in CONS [0.49 (0.12-0.89) to 1.38 (0.22-2.45) microg/l (P = 0.03)] and in NORMS [69 (0-320)% from 0.1 (< 0.1-0.13) to 0.17 (0.11-0.42) microg/l (P = 0.03)], but not in the LOWS.
1 context sentence(design, population, supporting numbers)
Summary · context
We performed a double-blind, randomized, placebo-controlled, cross-over study to investigate the effect of the GH receptor antagonist - pegvisomant (20 mg daily for 14 days) on GH and IGF-I levels in three cohorts: patients with GHD and a normal IGF-I (NORMS); patients with GHD and a low IGF-I (LOWS…
Report a problemFND-1906772806
07HumanNon-randomized trialEfficacy outcome
In healthy volunteers, pegvisomant increased arginine-stimulated peak GH from 6.1 to 20.4 microg/l (P = 0.03).
In plain wordsIn healthy volunteers, pegvisomant increased the peak growth hormone response to arginine.
Peptide
Pegvisomant
Outcome
IncreaseArginine-stimulated peak GH in healthy volunteers
Study
n: not reported in source
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
20 mg daily · 14 daysAs given in this study (human).
Measurements
Peak GH
6.1 microg/l
reference
Peak GH
20.4 microg/l
pegvisomant
Source sentences
Summary
The peak GH response to arginine was increased by pegvisomant in CONS and NORMS [6.1 (0.8-9) vs. 20.4 (13.1-28.8) microg/l, P = 0.03; 0.4 (0.1-0.5) vs. 0.5 (0.3-0.6) microg/l, respectively], but not in LOWS.
1 context sentence(design, population, supporting numbers)
Summary · context
We performed a double-blind, randomized, placebo-controlled, cross-over study to investigate the effect of the GH receptor antagonist - pegvisomant (20 mg daily for 14 days) on GH and IGF-I levels in three cohorts: patients with GHD and a normal IGF-I (NORMS); patients with GHD and a low IGF-I (LOWS…
Report a problemFND-1906772807
08HumanNon-randomized trialEfficacy outcome
In GHD patients with normal IGF-I, pegvisomant increased arginine-stimulated peak GH from 0.4 to 0.5 microg/l.
In plain wordsIn growth hormone deficiency with normal IGF-I, pegvisomant increased the peak growth hormone response to arginine.
Peptide
Pegvisomant
Outcome
IncreaseArginine-stimulated peak GH in normal-IGF-I GHD
Study
n: not reported in source
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
20 mg daily · 14 daysAs given in this study (human).
Measurements
Peak GH
0.4 microg/l
reference
Peak GH
0.5 microg/l
pegvisomant
Source sentences
Summary
The peak GH response to arginine was increased by pegvisomant in CONS and NORMS [6.1 (0.8-9) vs. 20.4 (13.1-28.8) microg/l, P = 0.03; 0.4 (0.1-0.5) vs. 0.5 (0.3-0.6) microg/l, respectively], but not in LOWS.
1 context sentence(design, population, supporting numbers)
Summary · context
We performed a double-blind, randomized, placebo-controlled, cross-over study to investigate the effect of the GH receptor antagonist - pegvisomant (20 mg daily for 14 days) on GH and IGF-I levels in three cohorts: patients with GHD and a normal IGF-I (NORMS); patients with GHD and a low IGF-I (LOWS…
Report a problemFND-1906772808
09HumanNon-randomized trialEfficacy outcome
In GHD patients with low IGF-I, pegvisomant did not increase the peak GH response to arginine.
In plain wordsIn growth hormone deficiency with low IGF-I, pegvisomant did not increase the peak growth hormone response to arginine.
Peptide
Pegvisomant
Outcome
No significant changeArginine-stimulated peak GH in low-IGF-I GHD
Study
n: not reported in source
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
20 mg daily · 14 daysAs given in this study (human).
Source sentences
Summary
The peak GH response to arginine was increased by pegvisomant in CONS and NORMS [6.1 (0.8-9) vs. 20.4 (13.1-28.8) microg/l, P = 0.03; 0.4 (0.1-0.5) vs. 0.5 (0.3-0.6) microg/l, respectively], but not in LOWS.
1 context sentence(design, population, supporting numbers)
Summary · context
We performed a double-blind, randomized, placebo-controlled, cross-over study to investigate the effect of the GH receptor antagonist - pegvisomant (20 mg daily for 14 days) on GH and IGF-I levels in three cohorts: patients with GHD and a normal IGF-I (NORMS); patients with GHD and a low IGF-I (LOWS…
Report a problemFND-1906772809

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:34 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.